SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NTII - Miscellaneous
NTII 0.00010000.0%Mar 7 3:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy2/3/2006 8:01:19 AM
   of 1296
 
2006

Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells.

Caumont AS, Octave JN, Hermans E.

Laboratoire de Pharmacologie Experimentale (FARL), Universite catholique de Louvain, Avenue Hippocrate 54.10, 1200 Bruxelles, Belgium.

Aminoadamantanes are commonly used in the treatment of Parkinson's and Alzheimer's diseases.

While these drugs are shown to antagonise ionotropic glutamate receptors on neuronal cells, additional mechanisms could contribute to their neuroprotective properties.

The aim of the present study was to investigate the effect of aminoadamantanes on the production of the glial cell line-derived neurotrophic factor (GDNF) in glial cells.

For this purpose, we measured the modulation of GDNF release in C6 glioma cell cultures treated for 24h with amantadine and memantine.

Both drugs dose-dependently increased GDNF level in the culture medium with similar potency (submicromolar range) and efficacy (three to four-fold induction).

RT-PCR studies revealed that both compounds also increased GDNF mRNA levels and their influence on the GDNF gene transcription was further evidenced using a rat GDNF promoter luciferase reporter assay.

Together, these results demonstrate that the neuroprotective effect of amantadine and memantine could involve the regulation of GDNF production by glial cells.

PMID: 16298481 [PubMed - in process]

ncbi.nlm.nih.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext